Motco Purchases 5,511 Shares of IQVIA Holdings Inc. $IQV

Motco grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 13.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 46,987 shares of the medical research company’s stock after acquiring an additional 5,511 shares during the quarter. Motco’s holdings in IQVIA were worth $7,405,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Everpar Advisors LLC boosted its position in shares of IQVIA by 4.6% during the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 62 shares during the last quarter. Private Trust Co. NA lifted its position in IQVIA by 12.5% in the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock worth $95,000 after buying an additional 67 shares during the last quarter. Ballentine Partners LLC lifted its position in IQVIA by 4.9% in the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock worth $260,000 after buying an additional 69 shares during the last quarter. Independent Advisor Alliance lifted its position in IQVIA by 4.2% in the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock worth $318,000 after buying an additional 72 shares during the last quarter. Finally, Nemes Rush Group LLC lifted its position in IQVIA by 15.0% in the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock worth $109,000 after buying an additional 81 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on IQV. UBS Group raised their price target on IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. Cowen restated a “buy” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Evercore ISI raised their price target on IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 8th. Barclays raised their price target on IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 2nd. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $234.57.

IQVIA Stock Performance

Shares of IQVIA stock opened at $218.26 on Wednesday. The firm has a market cap of $37.10 billion, a P/E ratio of 31.59, a P/E/G ratio of 2.39 and a beta of 1.32. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $225.91. The stock’s fifty day moving average price is $195.48 and its 200-day moving average price is $172.51.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.